Oral News and Research

RSS

Registration opens for The Endocrine Society's 2011 annual meeting in Boston

Media registration opens today for The Endocrine Society's 93rd Annual Meeting & EXPO taking place in Boston, MA on June 4-7, 2011. ENDO 2011 promises to be an engaging and informative opportunity for journalists to learn about the latest research in obesity, endocrine disrupters, diabetes, growth hormones, sex hormones, thyroid cancer and much more.

17 Feb 2011

Genomic Health to present prostate cancer studies at ASCO Genitourinary Cancer Symposium

Genomic Health, Inc. today announced the presentation of two studies at the American Society of Clinical Oncology® (ASCO®) Genitourinary (GU) Cancer Symposium, including complete results from its prostate cancer gene identification study, which identified 295 genes strongly associated with clinical recurrence following radical prostatectomy with great consistency across multiple tumor samples examined in each patient.

17 Feb 2011

Upcoming Bangladeshi mass cholera vaccine program might shed light on strategy effectiveness

TIME reports on an oral cholera vaccination program to kick off on Thursday in Bangladesh that researchers hope will determine how good of a "weapon" the mass vaccination strategy can be "against an old disease".

17 Feb 2011

New Rush clinic brings trained clinicians to care for patients with pulmonary hypertension

Cardiologists and pulmonologists at Rush University Medical Center have teamed up to provide a new and better approach to treating patients with pulmonary hypertension, a disease affecting the heart and lungs. The new Rush Pulmonary Hypertension Clinic brings together a multidisciplinary team of clinicians with specialized training to care for patients with this very complex disease.

16 Feb 2011

New study confirms effectiveness of inhaled epinephrine to treat croup

For more than 30 years, pediatricians have treated children who have croup with inhaled epinephrine to relieve their symptoms quickly. Now, a new review confirms the value of this approach to treat this common respiratory illness, which sometimes turns serious and - in rare instances - can prove fatal.

16 Feb 2011

Raptor reopens enrollment in DR Cysteamine Phase 3 trial to treat patients with nephropathic cystinosis

Raptor Pharmaceutical Corp., today announced it has reopened enrollment in its Phase 3 clinical trial of its proprietary delayed-release oral formulation of cysteamine bitartrate in patients with nephropathic cystinosis.

15 Feb 2011

US Oncology's PAPs help cancer patients to access high quality care

Through the continuous and tremendous growth of its patient assistance support program, US Oncology, Inc., a division of McKesson Corp. and a leading integrated oncology company, is helping cancer patients access the high quality cancer care they need. By helping patients obtain financial assistance, thousands can now afford much needed treatment and cancer therapies.

15 Feb 2011

Study confirms anti-inflammatory properties of Oligonol in humans

A recently published study in Nutrition Research and Practice has verified the anti-inflammatory effects in humans of Oligonol® lychee fruit polyphenol. The study examined Oligonol intake on cortisol and related cytokines in healthy young men. Both cortisol and cytokine concentrations are inflammatory markers known to increase when stress such as exercise is caused on the body.

15 Feb 2011

3M's Infection Prevention Division, Sage Products enter second agreement

Sage Products and 3M's Infection Prevention Division have entered into an agreement which includes sales representation of Sage Products by 3M in select international locations. The new agreement is the second collaboration announced by the two companies in recent months.

15 Feb 2011

Dabigatran drug helps prevent blood clots in patients with atrial fibrillation

The newly approved drug dabigatran is an alternative to warfarin to help prevent dangerous blood clots in patients with atrial fibrillation, according to updated guidelines from the American College of Cardiology, American Heart Association and the Heart Rhythm Society.

15 Feb 2011

Oral bisphosphonates outweigh the risk associated with jaw disease

A commonly prescribed osteoporosis drug is associated with a slightly elevated risk of developing the rare, but serious condition, osteonecrosis of the jaw; nonetheless the risk remains extremely low. These findings are published online in the Journal of Dental Research, the official journal of the International and American Associations for Dental Research.

14 Feb 2011

Tianyin Pharmaceutical's second quarter revenue increases 69.6% to $25.3 million

Tianyin Pharmaceutical Co., Inc., a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine, branded generics and other pharmaceuticals, announced the financial results for the second quarter of Fiscal Year 2011.

14 Feb 2011

Tarsa completes oral calcitonin Phase III trial for treatment of postmenopausal osteoporosis

Tarsa Therapeutics, Inc. today announced completion of its global Phase III ORACAL trial testing the company's once-daily oral recombinant calcitonin for the treatment of postmenopausal osteoporosis. Results from the ORACAL trial are expected in early spring. In addition, Tarsa announced initiation of a new Phase II study of its oral calcitonin for the prevention of postmenopausal osteoporosis.

14 Feb 2011

Elite third quarter consolidated revenues increase 34% to $1.2 million

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company dedicated to developing and commercializing oral controlled release product formulations, announced results for the fiscal third quarter ended December 31, 2011.

14 Feb 2011

JDR releases research report on Osteonecrosis of the jaw

Osteonecrosis of the jaw is a debilitating bone condition that affects the jaws and occurs as a result of reduced local blood supply to the bone. The literature in this area has been severely limited since most investigations cannot evaluate sufficient numbers of afflicted individuals to accurately determine the incidence of the disease and associated risk factors.

14 Feb 2011

Scientists produce SR-3306 compound to protect brain cells from Parkinson's disease

Scientists from the Florida campus of The Scripps Research Institute have produced the first known compound to show significant effectiveness in protecting brain cells directly affected by Parkinson's disease, a progressive and fatal neurodegenerative disorder.

13 Feb 2011

Vaccinating through salivary glands may provide protection against wide range of diseases

If you don't like shots or needles, you're in luck. New research published online in The FASEB Journal gives the development of new oral vaccinations a shot in the arm thanks to discoveries involving the salivary glands of mice. In addition, this research report also offers a tantalizing glimpse of vaccines that could prevent infection at mucosal surfaces, even if direct injections into the body fail to cause immunity. This technique may be effective for a wide range of diseases from influenza to cholera.

11 Feb 2011

Genetic testing for inherited blood-clotting abnormalities not routinely recommended for VTE patients

Genetic testing for inherited blood-clotting abnormalities is not routinely recommended for patients with venous thromboembolism (VTE) of unknown cause, according to a new expert panel statement in a recent issue of Genetics in Medicine, the official peer-reviewed journal of The American College of Medical Genetics (ACMG).

11 Feb 2011

FDA grants Inhibitex Fast Track Designation for INX-189 in treatment of chronic hepatitis C viral infection

Inhibitex, Inc. today reported that the U.S. Food and Drug Administration ("FDA") has designated the investigation of INX-08189, a potent guanosine nucleotide polymerase inhibitor for the treatment of chronic hepatitis C viral infection, as a Fast Track development program.

11 Feb 2011

Blocking interleukin 15 may help restore oral tolerance to gluten

Blocking a factor that can activate the human immune response against intestinal bacteria or certain foods could prevent the development of celiac disease in those most at risk, researchers report in the journal Nature.

11 Feb 2011

Oral News and Research

Registration opens for The Endocrine Society's 2011 annual meeting in Boston

Genomic Health to present prostate cancer studies at ASCO Genitourinary Cancer Symposium

Upcoming Bangladeshi mass cholera vaccine program might shed light on strategy effectiveness

New Rush clinic brings trained clinicians to care for patients with pulmonary hypertension

New study confirms effectiveness of inhaled epinephrine to treat croup

Raptor reopens enrollment in DR Cysteamine Phase 3 trial to treat patients with nephropathic cystinosis

US Oncology's PAPs help cancer patients to access high quality care

Study confirms anti-inflammatory properties of Oligonol in humans

3M's Infection Prevention Division, Sage Products enter second agreement

Dabigatran drug helps prevent blood clots in patients with atrial fibrillation

Oral bisphosphonates outweigh the risk associated with jaw disease

Tianyin Pharmaceutical's second quarter revenue increases 69.6% to $25.3 million

Tarsa completes oral calcitonin Phase III trial for treatment of postmenopausal osteoporosis

Elite third quarter consolidated revenues increase 34% to $1.2 million

JDR releases research report on Osteonecrosis of the jaw

Scientists produce SR-3306 compound to protect brain cells from Parkinson's disease

Vaccinating through salivary glands may provide protection against wide range of diseases

Genetic testing for inherited blood-clotting abnormalities not routinely recommended for VTE patients

FDA grants Inhibitex Fast Track Designation for INX-189 in treatment of chronic hepatitis C viral infection

Blocking interleukin 15 may help restore oral tolerance to gluten

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News